Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis

Gul Shahnaz, Benson J Edagwa, JoEllyn M McMillan, Sohail Akhtar, Abida Raza, Naveeda A. Qureshi, Masoom Yasinzai, Howard Eliot Gendelman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aim: Our goal was to improve treatment outcomes for visceral leishmaniasis by designing nanocarriers that improve drug biodistribution and half-life. Thus, long-acting mannose-anchored thiolated chitosan amphotericin B nanocarrier complexes (MTC AmB) were developed and characterized. Materials & methods: A mannose-anchored thiolated chitosan nanocarrier was manufactured and characterized. MTC AmB was examined for cytotoxicity, biocompatibility, uptake and antimicrobial activities. Results: MTC AmB was rod shaped with a size of 362 nm. MTC AmB elicited 90% macrophage viability and 71-fold enhancement in drug uptake compared with native drug. The antileishmanial IC50 for MTC AmB was 0.02 μg/ml compared with 0.26 μg/ml for native drug. Conclusion: These studies show that MTC can serve as a platform for clearance of Leishmania in macrophages.

Original languageEnglish (US)
Pages (from-to)99-115
Number of pages17
JournalNanomedicine
Volume12
Issue number2
DOIs
StatePublished - Jan 2017

Fingerprint

leishmaniasis
Visceral Leishmaniasis
Chitosan
Amphotericin B
Mannose
drug
Macrophages
Pharmaceutical Preparations
antimicrobial activity
half life
viability
Leishmania
Cytotoxicity
fold
Biocompatibility
Inhibitory Concentration 50
Half-Life

Keywords

  • amphotericin B
  • macrophage nanoparticle targeting
  • mannose receptors
  • thiolated chitosan
  • visceral leishmaniasis

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Cite this

Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. / Shahnaz, Gul; Edagwa, Benson J; McMillan, JoEllyn M; Akhtar, Sohail; Raza, Abida; Qureshi, Naveeda A.; Yasinzai, Masoom; Gendelman, Howard Eliot.

In: Nanomedicine, Vol. 12, No. 2, 01.2017, p. 99-115.

Research output: Contribution to journalArticle

Shahnaz, Gul ; Edagwa, Benson J ; McMillan, JoEllyn M ; Akhtar, Sohail ; Raza, Abida ; Qureshi, Naveeda A. ; Yasinzai, Masoom ; Gendelman, Howard Eliot. / Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. In: Nanomedicine. 2017 ; Vol. 12, No. 2. pp. 99-115.
@article{1c3bd8297dc74bd6a85f9fb54301ae42,
title = "Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis",
abstract = "Aim: Our goal was to improve treatment outcomes for visceral leishmaniasis by designing nanocarriers that improve drug biodistribution and half-life. Thus, long-acting mannose-anchored thiolated chitosan amphotericin B nanocarrier complexes (MTC AmB) were developed and characterized. Materials & methods: A mannose-anchored thiolated chitosan nanocarrier was manufactured and characterized. MTC AmB was examined for cytotoxicity, biocompatibility, uptake and antimicrobial activities. Results: MTC AmB was rod shaped with a size of 362 nm. MTC AmB elicited 90{\%} macrophage viability and 71-fold enhancement in drug uptake compared with native drug. The antileishmanial IC50 for MTC AmB was 0.02 μg/ml compared with 0.26 μg/ml for native drug. Conclusion: These studies show that MTC can serve as a platform for clearance of Leishmania in macrophages.",
keywords = "amphotericin B, macrophage nanoparticle targeting, mannose receptors, thiolated chitosan, visceral leishmaniasis",
author = "Gul Shahnaz and Edagwa, {Benson J} and McMillan, {JoEllyn M} and Sohail Akhtar and Abida Raza and Qureshi, {Naveeda A.} and Masoom Yasinzai and Gendelman, {Howard Eliot}",
year = "2017",
month = "1",
doi = "10.2217/nnm-2016-0325",
language = "English (US)",
volume = "12",
pages = "99--115",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis

AU - Shahnaz, Gul

AU - Edagwa, Benson J

AU - McMillan, JoEllyn M

AU - Akhtar, Sohail

AU - Raza, Abida

AU - Qureshi, Naveeda A.

AU - Yasinzai, Masoom

AU - Gendelman, Howard Eliot

PY - 2017/1

Y1 - 2017/1

N2 - Aim: Our goal was to improve treatment outcomes for visceral leishmaniasis by designing nanocarriers that improve drug biodistribution and half-life. Thus, long-acting mannose-anchored thiolated chitosan amphotericin B nanocarrier complexes (MTC AmB) were developed and characterized. Materials & methods: A mannose-anchored thiolated chitosan nanocarrier was manufactured and characterized. MTC AmB was examined for cytotoxicity, biocompatibility, uptake and antimicrobial activities. Results: MTC AmB was rod shaped with a size of 362 nm. MTC AmB elicited 90% macrophage viability and 71-fold enhancement in drug uptake compared with native drug. The antileishmanial IC50 for MTC AmB was 0.02 μg/ml compared with 0.26 μg/ml for native drug. Conclusion: These studies show that MTC can serve as a platform for clearance of Leishmania in macrophages.

AB - Aim: Our goal was to improve treatment outcomes for visceral leishmaniasis by designing nanocarriers that improve drug biodistribution and half-life. Thus, long-acting mannose-anchored thiolated chitosan amphotericin B nanocarrier complexes (MTC AmB) were developed and characterized. Materials & methods: A mannose-anchored thiolated chitosan nanocarrier was manufactured and characterized. MTC AmB was examined for cytotoxicity, biocompatibility, uptake and antimicrobial activities. Results: MTC AmB was rod shaped with a size of 362 nm. MTC AmB elicited 90% macrophage viability and 71-fold enhancement in drug uptake compared with native drug. The antileishmanial IC50 for MTC AmB was 0.02 μg/ml compared with 0.26 μg/ml for native drug. Conclusion: These studies show that MTC can serve as a platform for clearance of Leishmania in macrophages.

KW - amphotericin B

KW - macrophage nanoparticle targeting

KW - mannose receptors

KW - thiolated chitosan

KW - visceral leishmaniasis

UR - http://www.scopus.com/inward/record.url?scp=85003906123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003906123&partnerID=8YFLogxK

U2 - 10.2217/nnm-2016-0325

DO - 10.2217/nnm-2016-0325

M3 - Article

C2 - 27879160

AN - SCOPUS:85003906123

VL - 12

SP - 99

EP - 115

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 2

ER -